SYRS - Syros Pharmaceuticals GAAP EPS of -$0.17 beats by $1.13
- Syros Pharmaceuticals press release ( NASDAQ: SYRS ): Q4 GAAP EPS of -$0.17 beats by $1.13 .
- Cash, cash equivalents and marketable securities as of December 31, 2022 were $202.3 million, as compared with $143.4 million on December 31, 2021.
- Based on its current plans, Syros believes that its existing cash, cash equivalents and marketable securities will be sufficient to fund its anticipated operating expenses and capital expenditure requirements into the second quarter of 2025, beyond Phase 3 data from the SELECT-MDS-1 trial and initial data from the randomized portion of the SELECT-AML-1 trial.
For further details see:
Syros Pharmaceuticals GAAP EPS of -$0.17 beats by $1.13